Glaukos touts 2-year iStent inject pivotal trial data, levies infringement suit against Ivantis

April 16, 2018 By Fink Densford Leave a Comment

Glaukos (NYSE:GKOS) today released two-year data from the FDA investigational device exemption pivotal trial of its iStent inject trabecular micro-bypass system, and announced a patent infringement suit it filed against Ivantis.

Results of the 505-patient study were presented at the American Society of Cataracts and Refractive Surgery annual meeting by Dr. Thomas Samuelson of the Minnesota Eye Consultants, the San Clemente, Calif.-based company said.

The iStent inject trabecular micro-bypass system is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It uses a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows them to be injected into multiple trabecular meshwork locations via a single corneal entry point, the company said.

In the trial, subjects were randomized to two cohorts, with 387 patients receiving the iStent inject in combination with cataract surgery and 118 patients receiving cataract surgery only. Subjects in the trial were followed through two years with annual medication washouts, the company said.

Glaukos said that the trial met its primary and secondary effectiveness endpoints, and reported that the overall rate of adverse events between groups was similar.

At two years, 75.3% of the cohort who received the iStent inject achieved a 20% or greater reduction in unmedicated intraocular pressure compared to 61.9% in the cataract-surgery-only cohort. Mean unmedicated IOP amongst iStent patients was 6.9 mmHg compared to 5.4 mmHg for the cataract-only cohort.

Data indicated that at two years, the iStent inject cohort had a 31% mean reduction in unmedicated IOP of 17.11 mmHg from a baseline of 24.8 mmHG and that 62.6% of the cohort achieved an unmedicated mean IOP at or below 18 mmHg, compared to only 49.2% in the cataract-surgery-only cohort.

“The IOP-lowering capability of a single iStent in combination with cataract surgery has been well documented in the clinical literature, while various published studies and real-world international experience have also shown that multiple iStent devices can provide incremental IOP-lowering benefits. Given its performance and enhanced ease-of-use, we believe the iStent inject, if approved by the FDA, will be an attractive, two-stent option for U.S. ophthalmic surgeons to reliably manage glaucoma patients’ IOP in a straightforward and effective manner,” prez & CEO Thomas Burns said in a press release.

In a separate release, Glaukos announced it filed a patent infringement suit in the US District Court for the Central District of California, Southern division, against competitor Ivantis.

In the suit, the company claims that Ivantis’ Hydrus Microstent device infringes on patents Glaukos owns related to its core glaucoma technology.

“Since our founding in 1998, Glaukos has invested considerable time and resources to develop novel technologies that create entirely new treatment options for glaucoma surgeons and their patients. This lawsuit reflects our unwavering commitment to protect our proprietary inventions for the benefit of patients, customers, shareholders, employees and others who rely on us,” CEO Burns said in a prepared statement.

In February, Glaukos released results from a study of its iStent trabecular micro-bypass stent exploring its use during cataract surgery in patients with severe open-angle glaucoma, touting significant reductions in intraocular pressure and medication use.

Researchers develop speedy 3D printing
University of Michigan researchers said they have developed a 3D printing method that’s up to 100 times faster than conventional 3D printing processes. Rather than building up plastic filaments layer by layer, the new approach lifts complex shapes from a vat of liquid at high speed, potentially allowing manufacturers to produce up to 10,000 objects… […]
MTD Micro Molding named as Plastic News ‘Processor of the Year’ finalist
MTD Micro Molding (Charlton, Mass.) was recently named as one of Plastic News’s 2018 Processor of Year award finalists. MTD Micro Molding was a finalist in 2017 and 2015 as well. Plastic News awards the Processor of the Year award in polymer technologies to companies based on seven criteria: financial performance, quality, customer relations, employee relations,… […]
How AI can detect cervical cancer
Researchers have developed a computer algorithm that they say can analyze digital images of a woman’s cervix and accurately identify precancerous changes that require medical attention. This artificial intelligence approach, called automated visual evaluation, has the potential to revolutionize cervical cancer screening, particularly in low-resource settings. Led by investigators from the National Institutes of Health… […]
The state of M&A in medtech: Here’s what you may not know
Buyouts like Medtronic‘s (NYSE:MDT) $1.7 billion acquisition of Mazor Robotics (NSDQ:MZOR) dominated the headlines in 2018, but industry veteran Shayan Bhattacharyya found himself intrigued by the smaller deals that didn’t make the press. “The things that keep me interested are the deals that are the tuck-in, bolt-on acquisitions,” Bhattacharyya said at DeviceTalks West in Costa Mesa, Calif., last month. (Bhattacharyya… […]
Laird Thermal Systems launches new website
Laird Thermal Systems has launched its new website with advanced engineering tools. The new website allows design engineers to specify, search and select the optimum thermoelectric module, thermoelectric assembly or liquid cooling system for various applications. Laird Thermal Systems also suggests that the website can shorten product design cycles while improving product or system performance… […]
5 top stories that mattered for medtech in 2018
The medical device industry faced some major challenges over the past year, from increased media scrutiny to regulatory uncertainty in both the U.S. and E.U. It’s worth noting, though, that many things have been going right for medtech. More than half of the roughly 100 largest medical device companies in the world saw their stock… […]
Instron touts Torsion Add-On 2.0 for biaxial testing
Instron has launched its new Torsion Add-On 2.0 for universal testing machines. The new add-on is designed to convert axial-only testing machines into biaxial systems that can simulate real-world use of multi-axis loading products. It is able to be added to new or existing Instron 5940 or 5960 series tabletop universal testing machines. Instron’s new… […]
FDA adds back some workers during partial government shutdown
The FDA has resumed several health and safety activities that had been halted by the partial government shutdown, now in its 24th day. In a series of tweets on Sunday, FDA Commissioner Scott Gottlieb, M.D. listed the tasks that the agency has added to “excepted, unpaid work.” “It is not business as usual at FDA.… […]
Presbia reaches ISO medical device quality milestone
Presbia (Nasdaq:LENS) said today that it has successfully completed the ISO 13485:2016 audit with no major findings. Officials at the Dublin, Ireland–based ophthalmic device company described the audit completion as an essential step toward recertifying under the ISO standard. The company – which has administrative offices and manufacturing in Irvine, Calif. – will receive annual surveillance… […]
Cook Medical to market Zelegent’s ‘facelift for the soft palate’
Just a month after receiving FDA 510(k) approval for its new anti-snoring device, startup Zelegent has signed a marketing agreement with Cook Medical, the companies announced. Zelegent’s Elevo kit snoring intervention device employs specially shaped, resorbable, barbed sutures to lift the soft palate by1-4 millimeters, expanding the mean diameter of the airway. In a typical snoring patient… […]
Avita Medical launches ReCell System in U.S.
Avita Medical (Cambridge, U.K.) has launched its ReCell Autologous Cell Harvesting Device in the U.S. The system is designed to threat acute thermal burns in patients who are 18 years or older. So far, 36 burns centers have started the purchase authorization process with hospital administrations, 25 burn centers have been trained and certified to use… […]